The University of Southampton
University of Southampton Institutional Repository

Treatment of infants with lymphoblastic leukaemia: results of the UK Infant Protocols 1987-1999

Treatment of infants with lymphoblastic leukaemia: results of the UK Infant Protocols 1987-1999
Treatment of infants with lymphoblastic leukaemia: results of the UK Infant Protocols 1987-1999
One hundred and twenty-six infants with acute lymphoblastic leukaemia (ALL) were treated on two consecutive protocols, Infant 87 (n = 40) and Infant 92 (n = 86), in an attempt to improve the poor prognosis of this disease. Both included intensive induction and consolidation with intrathecal and high-dose systemic therapy for central nervous system (CNS) protection. Intensification therapy was modified and high-dose chemotherapy with bone marrow transplantation in first remission was permitted in Infant 92. Four-year event-free survival was superior in Infant 92 (33%; 95% CI 23–44%) compared with Infant 87 (22·5%; 95% CI 12–37%) (P = 0·04) and survival at 4 years was also superior, 46% (95% CI 35–57%) c.f. 32·5% (95% CI 20–48%) (P = 0·01), largely as a result of a significant reduction in remission deaths. Twelve patients in Infant 92 underwent bone marrow transplantation (BMT) in first remission, but their survival was no better than that of patients receiving chemotherapy. Multivariate analysis of prognostic factors showed the adverse influence of younger age, CNS involvement at diagnosis and a high initial leucocyte count, but not of CD10 expression. Cytogenetic analysis, available in 93% of patients in Infant 92, showed that 67% had chromosomal rearrangements involving 11q23 of which 39% had the translocation t(4;11) (q21;q23). There was no significant difference in event-free survival between cytogenetic subgroups, although no children under 6 months of age with 11q23 abnormalities, other than the t(4;11), survived. In conclusion, infants with lymphoblastic leukaemia remain a high-risk group, but it is unclear whether their adverse prognosis can be attributed to unfavourable cytogenetics alone. The role of high-dose therapy and BMT in first remission remains uncertain.
infant lymphoblastic leukaemia, prognosis, treatment
0007-1048
306-314
Chessells, J. M.
97ab84c4-c8ce-490b-baa8-89ea4c12c50f
Harrison, C. J.
611341f5-5e07-4a91-9694-b548d13677a5
Watson, S. L.
a1552ce2-8aea-4878-8a6d-db4bfb4a27fc
Vora, A. J.
00eb2d49-1597-4dc2-adcb-24c32c605abc
Richards, S. M.
48f05f2f-aa93-45a8-92c8-f421ffea42fb
Chessells, J. M.
97ab84c4-c8ce-490b-baa8-89ea4c12c50f
Harrison, C. J.
611341f5-5e07-4a91-9694-b548d13677a5
Watson, S. L.
a1552ce2-8aea-4878-8a6d-db4bfb4a27fc
Vora, A. J.
00eb2d49-1597-4dc2-adcb-24c32c605abc
Richards, S. M.
48f05f2f-aa93-45a8-92c8-f421ffea42fb

Chessells, J. M., Harrison, C. J., Watson, S. L., Vora, A. J. and Richards, S. M. (2002) Treatment of infants with lymphoblastic leukaemia: results of the UK Infant Protocols 1987-1999. British Journal of Haematology, 117 (2), 306-314. (doi:10.1046/j.1365-2141.2002.03442.x).

Record type: Article

Abstract

One hundred and twenty-six infants with acute lymphoblastic leukaemia (ALL) were treated on two consecutive protocols, Infant 87 (n = 40) and Infant 92 (n = 86), in an attempt to improve the poor prognosis of this disease. Both included intensive induction and consolidation with intrathecal and high-dose systemic therapy for central nervous system (CNS) protection. Intensification therapy was modified and high-dose chemotherapy with bone marrow transplantation in first remission was permitted in Infant 92. Four-year event-free survival was superior in Infant 92 (33%; 95% CI 23–44%) compared with Infant 87 (22·5%; 95% CI 12–37%) (P = 0·04) and survival at 4 years was also superior, 46% (95% CI 35–57%) c.f. 32·5% (95% CI 20–48%) (P = 0·01), largely as a result of a significant reduction in remission deaths. Twelve patients in Infant 92 underwent bone marrow transplantation (BMT) in first remission, but their survival was no better than that of patients receiving chemotherapy. Multivariate analysis of prognostic factors showed the adverse influence of younger age, CNS involvement at diagnosis and a high initial leucocyte count, but not of CD10 expression. Cytogenetic analysis, available in 93% of patients in Infant 92, showed that 67% had chromosomal rearrangements involving 11q23 of which 39% had the translocation t(4;11) (q21;q23). There was no significant difference in event-free survival between cytogenetic subgroups, although no children under 6 months of age with 11q23 abnormalities, other than the t(4;11), survived. In conclusion, infants with lymphoblastic leukaemia remain a high-risk group, but it is unclear whether their adverse prognosis can be attributed to unfavourable cytogenetics alone. The role of high-dose therapy and BMT in first remission remains uncertain.

Full text not available from this repository.

More information

Published date: 2002
Keywords: infant lymphoblastic leukaemia, prognosis, treatment

Identifiers

Local EPrints ID: 26245
URI: http://eprints.soton.ac.uk/id/eprint/26245
ISSN: 0007-1048
PURE UUID: 11b1cce9-c86d-4808-b2ab-c29ce980d66b

Catalogue record

Date deposited: 21 Apr 2006
Last modified: 15 Jul 2019 19:14

Export record

Altmetrics

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×